Vera Therapeutics (VERA) Competitors $23.74 +0.10 (+0.40%) Closing price 07/3/2025 03:35 PM EasternExtended Trading$23.74 0.00 (0.00%) As of 07/3/2025 04:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock VERA vs. NUVL, AXSM, AKRO, PCVX, ADMA, KRYS, ZLAB, RYTM, PTCT, and CYTKShould you be buying Vera Therapeutics stock or one of its competitors? The main competitors of Vera Therapeutics include Nuvalent (NUVL), Axsome Therapeutics (AXSM), Akero Therapeutics (AKRO), Vaxcyte (PCVX), ADMA Biologics (ADMA), Krystal Biotech (KRYS), Zai Lab (ZLAB), Rhythm Pharmaceuticals (RYTM), PTC Therapeutics (PTCT), and Cytokinetics (CYTK). These companies are all part of the "pharmaceutical products" industry. Vera Therapeutics vs. Its Competitors Nuvalent Axsome Therapeutics Akero Therapeutics Vaxcyte ADMA Biologics Krystal Biotech Zai Lab Rhythm Pharmaceuticals PTC Therapeutics Cytokinetics Nuvalent (NASDAQ:NUVL) and Vera Therapeutics (NASDAQ:VERA) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, valuation, earnings, dividends and media sentiment. Do institutionals and insiders have more ownership in NUVL or VERA? 97.3% of Nuvalent shares are held by institutional investors. Comparatively, 99.2% of Vera Therapeutics shares are held by institutional investors. 10.2% of Nuvalent shares are held by insiders. Comparatively, 16.3% of Vera Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has stronger valuation & earnings, NUVL or VERA? Nuvalent is trading at a lower price-to-earnings ratio than Vera Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNuvalentN/AN/A-$260.76M-$4.39-18.31Vera TherapeuticsN/AN/A-$152.15M-$3.00-7.92 Which has more risk and volatility, NUVL or VERA? Nuvalent has a beta of 1.31, suggesting that its share price is 31% more volatile than the S&P 500. Comparatively, Vera Therapeutics has a beta of 1.19, suggesting that its share price is 19% more volatile than the S&P 500. Is NUVL or VERA more profitable? Nuvalent's return on equity of -31.35% beat Vera Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets NuvalentN/A -31.35% -29.27% Vera Therapeutics N/A -40.59%-34.54% Does the media favor NUVL or VERA? In the previous week, Nuvalent had 6 more articles in the media than Vera Therapeutics. MarketBeat recorded 8 mentions for Nuvalent and 2 mentions for Vera Therapeutics. Vera Therapeutics' average media sentiment score of 0.67 beat Nuvalent's score of 0.35 indicating that Vera Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nuvalent 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Vera Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend NUVL or VERA? Nuvalent presently has a consensus price target of $119.60, suggesting a potential upside of 48.82%. Vera Therapeutics has a consensus price target of $65.00, suggesting a potential upside of 173.74%. Given Vera Therapeutics' higher possible upside, analysts plainly believe Vera Therapeutics is more favorable than Nuvalent.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nuvalent 0 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 2 Strong Buy rating(s) 3.17Vera Therapeutics 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 2 Strong Buy rating(s) 3.10 SummaryVera Therapeutics beats Nuvalent on 7 of the 13 factors compared between the two stocks. Get Vera Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VERA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VERA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VERA vs. The Competition Export to ExcelMetricVera TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.53B$2.91B$5.55B$9.04BDividend YieldN/A2.44%5.22%3.99%P/E Ratio-7.9221.5627.6620.24Price / SalesN/A280.51419.21118.06Price / CashN/A42.7336.8958.10Price / Book2.627.518.035.67Net Income-$152.15M-$55.14M$3.18B$249.21M7 Day Performance4.83%4.61%2.93%3.28%1 Month Performance4.60%0.90%1.72%3.95%1 Year Performance-33.36%5.40%34.39%20.98% Vera Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VERAVera Therapeutics3.3743 of 5 stars$23.75+0.4%$65.00+173.7%-33.4%$1.53BN/A-7.9240NUVLNuvalent3.7354 of 5 stars$75.98+1.3%$115.50+52.0%+10.3%$5.46BN/A-17.3140Insider TradeAXSMAxsome Therapeutics4.7454 of 5 stars$101.65+1.0%$172.33+69.5%+28.5%$5.01B$385.69M-17.62380Trending NewsAnalyst ForecastAnalyst RevisionAKROAkero Therapeutics3.4647 of 5 stars$54.03-0.3%$82.50+52.7%+142.5%$4.31BN/A-27.7130Insider TradePCVXVaxcyte1.7889 of 5 stars$33.25+1.2%$136.50+310.5%-57.3%$4.29BN/A-8.33160News CoverageADMAADMA Biologics4.1393 of 5 stars$17.87+0.7%$27.67+54.8%+59.6%$4.27B$426.45M21.02530Positive NewsKRYSKrystal Biotech4.5837 of 5 stars$137.92+4.1%$211.13+53.1%-22.4%$3.99B$290.52M33.15210News CoverageAnalyst RevisionHigh Trading VolumeZLABZai Lab3.4324 of 5 stars$36.01+4.2%$47.37+31.5%+110.3%$3.97B$398.99M-14.461,869News CoveragePositive NewsInsider TradeAnalyst RevisionGap UpRYTMRhythm Pharmaceuticals3.8085 of 5 stars$62.13+0.2%$76.62+23.3%+55.6%$3.95B$130.13M-22.11140News CoveragePositive NewsPTCTPTC Therapeutics4.3173 of 5 stars$49.60-1.2%$65.00+31.0%+57.7%$3.93B$806.78M7.621,410Analyst RevisionCYTKCytokinetics3.9316 of 5 stars$32.64+0.6%$70.92+117.3%-38.9%$3.90B$18.47M-6.17250 Related Companies and Tools Related Companies Nuvalent Competitors Axsome Therapeutics Competitors Akero Therapeutics Competitors Vaxcyte Competitors ADMA Biologics Competitors Krystal Biotech Competitors Zai Lab Competitors Rhythm Pharmaceuticals Competitors PTC Therapeutics Competitors Cytokinetics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VERA) was last updated on 7/6/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored140% Yields From Stocks Like Tesla? Here's How (July 4th Special)Imagine getting a 140% dividend from your investments. Even better? It works with big names like Tesla, ...Investors Alley | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredThe day and month stocks are most likely to crash nextGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history giv...Chaikin Analytics | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vera Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vera Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
